Sep

26

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the initiation of a Phase III clinical trial of the Company’s novel octreotide implant for acromegaly.
 

This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly.  The implant utilizes the company’s patented HYDRON(R) Polymer Technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide that mimics the natural hormone somatostatin to suppress release of human growth hormone (GH).

Want to read about the benefits of the top selling hgh product which does not cause any unwanted side effects? Clcik here to read more!

Read the entire earthtimes.org/hgh article


Comments

Name (required)

Email (required)

Website

Speak your mind

Comments are closed.